Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087867
Status:
COMPLETED
Last Update Posted:
2010-10-18
First Post:
2004-07-14
Brief Title:
Study of Oral SCIO-469 in Relapsed Refractory Patients With Multiple Myeloma
Sponsor:
Scios Inc
Organization:
Scios Inc
Study Overview
Official Title:
An Open-label Study of the Efficacy Safety and Tolerability of Oral SCIO-469 in Treatment of Relapsed Refractory Patients With Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed refractory patients with multiple myeloma MM based on response rates
Detailed Description:
The main objective of this study is to assess the efficacy of SCIO-469 as monotherapy in relapsed refractory patients with multiple myeloma MM based on response rates Patients took SCIO-469 two capsules 60 mg by mouth three times a day with water preferably with a meal for 72 days except on Days 1 and 30 of monotherapy and Days 1 and 11 of combination therapy On these days the second dose of SCIO-469 was administered after collection of the 12-hour PK sample and the third dose was not administered
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SCIO-469MMY2001 B003 | None | None | None |